Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Research & Development (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Research & Development readings, the most recent being $77.9 million for Q4 2025.

  • Quarterly Research & Development rose 11.09% to $77.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $77.9 million through Dec 2025, up 11.09% year-over-year, with the annual reading at $77.9 million for FY2025, 11.09% up from the prior year.
  • Research & Development hit $77.9 million in Q4 2025 for Terns Pharmaceuticals, up from $70.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $77.9 million in Q4 2025 and bottomed at $6.0 million in Q2 2021.
  • Average Research & Development over 5 years is $35.0 million, with a median of $23.4 million recorded in 2021.
  • The largest annual shift saw Research & Development decreased 21.68% in 2021 before it surged 295.44% in 2022.
  • Terns Pharmaceuticals' Research & Development stood at $9.5 million in 2021, then surged by 295.44% to $37.4 million in 2022, then skyrocketed by 69.7% to $63.5 million in 2023, then grew by 10.42% to $70.1 million in 2024, then rose by 11.09% to $77.9 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Research & Development are $77.9 million (Q4 2025), $70.1 million (Q4 2024), and $63.5 million (Q4 2023).